Annexon highlights strategic focus to advance four flagship complement programs through late-stage development and progress across three therapeutic franchises

Mid-stage and pivotal trials of anx005, anx007 and anx1502 poised to achieve numerous catalysts in multiple disease indications
ANNX Ratings Summary
ANNX Quant Ranking